

ENDOVISION

Endoscopy Quality Control

with **AI Software**

CLINICAL FOCUS


Reduce blind spots in upper GI Endoscopy

CERTIFICATION

Approved Class IIa SaMD in Europe

PARTNERSHIP


Strategic Medtronic Collaboration 🤝



The Clinical Challenge: Blind Spots & Late Detection

01 / Endoscopy

Standard Procedure



Diagnostic Examination

Standard digestive tract diagnostic procedure, heavily reliant on manual operator technique.

02 / The Danger

Missed Cancers



Unstructured Coverage

Significant percentage of mucosal surface is missed due to operator blind spots and lack of tracking.

03 / Consequences

Late-Stage Mortality



3rd Leading Cause of Death

Usually detected at late stages where the survival rate drops dramatically from 95% down to just 6%.



Solution: AI-Driven Standardization

Doctor + AI combination enforces systematic quality control, effectively eliminating blind spots in real-time.

Product Demo and clinical usage

LANDMARKS

Observed Landmarks Tracking

Automated real-time recognition and tracking of crucial anatomical sites.

DOCUMENTATION


Manual Photodoc Tracking

Ensures standardized capture of key procedural events and steps.

FEEDBACK

Actionable Clinical Prompts

Provides real-time feedback for rinsing, inflation, and completeness.



[CLICK TO VIEW](#)

CLINICAL DEMONSTRATION

Clinical usage demo

Systematic quality control operating live within standard-of-care workflows to eliminate blind spots.




[CLICK TO VIEW](#)

Clinical Milestones


Validation Study

3 expert endoscopists marked the 100 EGD videos with varied abnormalities. Validated AI on anatomical site recognition.



Clinical Study: Proven Quality Improvement

82.2% detection rate with AI vs. 75% with control. 466 EGDs conducted by 8 trainee endoscopists. Engine powered by a 30,000+ patient database.



Chan SM, Chan D, Yip HC, Scheppach MW, Lam R, Ng SK, Ng EKW, Chiu PW. Artificial intelligence-assisted esophagogastroduodenoscopy improves procedure quality for endoscopists in early stages of training. *Endosc Int Open*. 2025 Apr 15;13:a25476645. doi: 10.1055/a-2547-6645. PMID: 40309064; PMCID: PMC12042994.

Market Opportunity

Sizing our trajectory in a rapidly expanding endoscopy landscape



★ **25.8% CAGR** Growth Engine Driving Expansion

TAM: Total Device Market

The global endoscopy device market size, establishing the baseline physical infrastructure.

Broadest addressable market

SAM: AI in Endoscopy

Specific addressable market for Software as a Medical Device (SaMD) applications in endoscopy.

Target software segment


SOM: Obtainable Market Size

Immediate achievable market including EU and US regions optimized for 2 core product lines.

Initial target trajectory

Strategic Positioning & Ecosystem

Endovision as the foundational, brand-agnostic quality control software layer



The 'Collaborator, Not Competitor' Hub

"Foundation, not Replacement: We standardize procedure quality; our partners deliver it."

Product Focus: Quality over Detection

Others (Detection / CAdE)

- Focused heavily on spotting polyps

Highly commoditized space driven by hardware-bound algorithms.

Us / Endovision (CAQ)

- Quality Control & Blind Spot Elimination

Proprietary & foundational brand-agnostic software layer.


Industry First: CE/MDR Regulatory Moat

First CAQ solution with robust regulatory approval, cementing our first-mover advantage.

Because we are brand-agnostic, Endovision serves as a neutral ecosystem partner that drives system-wide quality without threatening hardware giants.

Strategic Positioning & Ecosystem

Endovision as the foundational, brand-agnostic quality control software layer



The 'Collaborator, Not Competitor' Hub

"Foundation, not Replacement: We standardize procedure quality; our partners deliver it."

Product Focus: Quality over Detection

Others (Detection / CAdE)

- Focused heavily on spotting polyps

Highly commoditized space driven by hardware-bound algorithms.

Us / Endovision (CAQ)

- Quality Control & Blind Spot Elimination

Proprietary & foundational brand-agnostic software layer.

Commercial Strategy & Market Entry

Partnership ecosystem, SaaS pricing, and global scale execution



Business Model

 **Revenue:** Recurring SaaS (\$1k/mo per system).

 **Royalty:** Tiered Model (Confidential).

 **Strategy:** Strategic Partnership (Medtronic/Cosmo).

Market Entry Execution

**Cosmo Announces EU MDR
Certification for Endovision's
Cerebro, expanding its real-time
AI ecosystem**

Immediate Focus:

Limited Market Release (LMR) in Europe.

Strategic Moat:

Leveraging 2,000+ existing GI-Genius install base.

Global Scaling:

Expansion into 40+ countries via established networks.



Regulatory Milestones & Roadmap

Approved in Europe, global compliance and preparing for US FDA market entry

Established Foundation

2023

ISO 13485:2016
Certified Quality Mgmt

Oct 2024

Approval in India
Regulatory Milestone

Jan 2025

Clinical Study
Successful Completion

European Expansion

July 2025

CE Mark (MDR)
Regulatory Approval

Jan 2026

Medtronic Alliance
Distribution Secured

Dec 2026

EU Market Launch
With Medtronic Pipeline

US FDA Pathway

Q4 2027

FDA Clinical Study
Target Completion

Q1 2028

Official FDA Filing
Submission Process

Q2 2028

FDA Approval
Anticipated Market Entry

Technical Roadmap

Q1 2027

Early Gastric Cancer
Detection & Characterization

Q2 2027

AutoDoc
Automated Reporting Module

2027+

Further CADe Solutions
Expanded AI Detection Suite

Defensible Moat

Why Endovision AI is built to outpace competition and cannot be easily copied



The AI Engine

30k+ Patient Data Asset


We possess more than **30k** high-quality patient data from diverse endoscopy types, establishing a proprietary foundation that competitors cannot easily replicate or acquire.



Factory Scaling

AI Dev Ecosystem

Robust backend architecture—from scalable ML pipelines to simulation environments. Fast-tracked and highly leveraged by elite Hong Kong grant ecosystems (Science Park).



The Tech Edge

Real-Time Video AI

Technological core differentiation: highly optimized algorithms capable of extracting clinical features from video feeds in absolute real time with precision accuracy.

Dream Team: Execution Power + Expert Backing

Combining agile, deep-tech founders with world-class clinical and strategic advisors

PROVEN FOUNDERS & SYNERGY



Saurabh Jejurikar | CEO & Product Leader

- M.Sc. Mathematics & B.E. EEE (BITS Pilani)
- Serial Entrepreneur: Previously founded a venture-backed startup with 25k+ users
- Gastro-Family Background with direct clinical network to top-tier hospitals

Synergy: Bridges high-scale software execution with key clinical partnerships

[LinkedIn](https://www.linkedin.com/in/saurabh-jejurikar-78076b97): [linkedin.com/in/saurabh-jejurikar-78076b97](https://www.linkedin.com/in/saurabh-jejurikar-78076b97)



Deepanshu Malik | CTO (Deep Tech & AI)

- Masters in High-Performance Computing from University of Southern California
- Built autonomous driving CV software at Here Technologies (Silicon Valley)
- 15+ years of specialized deep-tech and AI architecture experience

Synergy: Translates complex clinical requirements into real-time computer vision

STRATEGIC BACKING & ADVISORS



Prof. Philip Chiu

Clinical Scientific Advisor

Director of Endoscopy, PWH, HK PI
27 years of clinical endoscopy experience
guiding medical validation



Prof. Kenshi Yao

Clinical Scientific Advisor

Director of Endoscopy, Fukuoka Hospital,
Japan
30 years of experience in endoscopy, steering
global clinical strategy



Dr. Mahesh Goenka

Clinical Scientific Advisor

President of Indian Gastroenterology Society
Renowned medical pioneer driving regulatory
support and adoption

Cosmo Pharma Team

Regulatory & Approvals Team

Reputable Medical Regulatory Experts
Pioneered & successfully guided the
first-in-market AI in endoscopy

Funding Opportunity: \$1M Bridge Round

60% Committed

Closing our Bridge round to accelerate clinical validation and commercial expansion



FDA Approval

Groundwork Complete

Leveraging world-class clinical data to fast-track submission with FDA clearance anticipated soon.



European Scaling

Commercial Traction

Scaling through established global distribution agreements with Medtronic and Cosmo Pharma.



Pipeline Conversion

Product Evolution

Finalizing near-completion AI solutions (CADe/Auto-reporting) into commercial products.